Please click on an icon below to view our free company specific research and monthly newsletter. You must be a registered user on our website to access the research and newsletter.
Please visit our industry pages, where we provide investment considerations, daily stories, videos & more for the 12 industries listed below:
A Vista Partners’ Commentary “3rd Annual Sickle Cell Disease Therapeutics Conference Being Held in NYC September 15, 2014″July 30, 2014 by jheerdink
San Diego, California based biotechnology firm Mast Therapeutics, Inc. (NYSE MKT: MSTX) is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes.
Who We Are
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm’s professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista’s mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes. CLICK HERE to view past performance.